German biopharma services company Sartorius is to spend three-quarters of a billion dollars to buy up Danaher’s life science portfolio.
This comes as part of a deal in which Danaher, another biopharma services company, is itself in the middle of: buying the biopharma business of GE Life Sciences for around $20 billion. This sell-off to Sartorius has been promoted by the GE deal, likely appeasing regulators.
The deal is set to include the label-free biomolecular characterization (known as FortéBio), chromatography hardware and resins, and microcarriers (known as SoloHill) businesses.
The deal, which hinges upon the GE buyout completing, should be done by the first quarter next year.
“The portfolio proposed for acquisition represents an excellent strategic fit with Sartorius,” said Dr. Joachim Kreuzburg, Sartorius’ CEO.
“With the Octet platform of FortéBio, we will add a broadly accepted and differentiated technology for advancing and simplifying drug discovery to our lab division’s portfolio. The chromatography hardware and resins and the microcarrier businesses broaden our strong bioprocessing offering, particularly in the downstream area. We look very much forward to welcoming the new teams to Sartorius and to jointly combine our capabilities for the benefit of our biopharma and life science customers.”